6000th Stratus OCT System Installed at Cleveland Eye Clinic

A milestone was reached in November when the 6,000th Stratus OCT System was installed at the Cleveland Eye Clinic. More than 37,000 scans are performed daily in the U.S. alone using the Stratus OCT which has become the standard of care for a wide variety of ophthalmic applications.



(from left to right) Chuck McVeigh, Administrator of the Cleveland Eye Clinic; John Alberini, Carl Zeiss Meditec representative; and Dr. Troy Bornhorst, Dr. William Wiley, and Dr. Thomas Chester of the Cleveland Eye Clinic, commemorate the installation of the 6,000th Stratus OCT.

The Stratus OCT, which was granted FDA clearance in January 2002, incorporates optical coherence tomography to provide comprehensive imaging and measurement of glaucoma and retinal disease.

"We purchased the Stratus OCT because of its high level of diagnostic information, which provides us with significantly more data to help confirm diagnoses," said William Wiley, M.D., medical director of the Cleveland Eye Clinic. "This is clearly an exciting time for leading-edge technological solutions such as the Stratus OCT."

Thomas Chester, OD, FAAO, clinical director of the Cleveland Eye Clinic said, "The system enhances our diagnostic abilities for glaucoma patients, diabetic patients and patients with other retinal pathologies."

Stratus OCT Instrumental in Guiding Lucentis Treatment of Neovascular AMD

The emergence of anti-VEGF agents such as Ranibizumab (Genentech Lucentis™) as first line agents for the treatment of choroidal neovascularization in macular degeneration has prompted retinal specialists to ask an important question: what is the best strategy for deciding which eyes to treat and, following initial treatment, when to initiate retreatment?

Dr. Philip Rosenfeld and colleagues at Bascom Palmer Eye Institute have suggested that most retreatment decisions can be made using two clinical data points: 1. decline in visual acuity and 2. increase in retinal thickness as detected by optical coherence tomography (OCT) in those eyes that have experienced an improvement in retinal anatomy after initial therapy.

This information is the result of a variable-dosing, open-label uncontrolled study of 40 patients conducted at Bascom Palmer Eye Institute. In this two-year study, Stratus OCT was used to determine when retreatment was necessary over two years. The visual acuity and OCT outcomes in the study were achieved with an average of 5.6 injections over 12 months versus 12 consecutive monthly injections in the original ranibizumab protocol.

"By using the Stratus OCT to follow patients, we were able to take advantage of this non-invasive, quantitative and qualitative imaging technique to give fewer injections compared with the standard monthly dosing regimen, and for a majority of the patients, obtain visual improvement comparable to the monthly dosing regimen," said Dr. Rosenfeld.